03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Rare diseases
Conxi Lázaro
co-leader of the Hereditary Cancer group at IDIBELL and ICO and member of REMMA Bellvitge
press citation on 1 topic since 22 Jun 2026 · last quoted 22 Jun 2026
02 Quoted on · 1 of 29 topics
Conxi Lázaro: key facts
- Kind of voice
- Academic
- Role
- co-leader of the Hereditary Cancer group at IDIBELL and ICO and member of REMMA Bellvitge
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 22 Jun 2026
04 The signal · where Conxi Lázaro sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Dr. Sarawut BoonsukSector leaderDirector-General of Thailand's Department of Medical Sciences1
- 25=Tarun DuaAcademicUnit Head of Brain Health at the World Health Organization and colead of the WHO Global Action Plan for Rare Diseases1
- 25=Conxi LázaroAcademicco-leader of the Hereditary Cancer group at IDIBELL and ICO and member of REMMA Bellvitge1
- 25=Eduard SerraAcademicIGTP researcher and co-lead author of the study1
- 25=Itziar UriarteAcademicfirst author of the work1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Conxi Lázaro has said
- idibell.cat1
Where Conxi Lázaro has been quoted
- 01An innovative cell model allows progress in the research of a rare diseaseidibell.cat · 22 Jun 2026
Verbatim
“The model developed has allowed us not only to study how malignant transformation occurs in NF1, but also to identify potential therapeutic vulnerabilities”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.